ZS805 / Zhishan Weixin Bio - LARVOL DELTA

rAAV Gene Therapy for Classic Fabry Disease: ZS805 Results from An Ongoing Investigator-Initiated Clinical Trial (ASGCT 2025) - P=N/A | "Ten patients were given a prednisone prophylactic treatment one week prior to injection while one patient had no prednisone prophylactic treatment. ZS805 was well tolerated at both dosage levels. The α-Gal A activity remained stable and sustained in two participants for more than 52 weeks. The level of plasma Lyso-GL-3 significantly decreased."

Clinical • Gene therapy • Fabry Disease • Gene Therapies • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases